Compound (E)-2f stands out among the synthesized inhibitors as a promising GSK3β inhibitor (IC50 1.7 μM) with a pronounced tau anti-aggregation effect in a cell-based model of tauopathy. The gene discussed is MAPT; the disease is tauopathy.